A Phase 2 interventional study of FT007 in Transfusion-dependent Beta-Thalassemia, sponsored by Fondazione Telethon. Recruiting at 2 sites in Italy. Open to participants aged 3 Years to 35 Years. Per ClinicalTrials.gov, last updated 2026-07-27.
Sponsored by Fondazione Telethon · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 49 studies in beta-Thalassemia with a site in Italy — 8 open to participants now, 17 under way, 6 of them phase 3. beta-Thalassemia · Italy.
Among the 49 studies in beta-Thalassemia with a site in Italy, this one is the 38th largest by planned enrollment of the 39 interventional ones that give a count, is the only one that started in 2026, is one of 18 in phase 2, reaches primary completion later than 14 of the 16 other live ones, and was the 49th registered.
295 studies on the registry are indexed under beta-Thalassemia; 70 are open to participants now.
Browse beta-Thalassemia studies →8 of the 49 studies in beta-Thalassemia with a site in Italy are open now. Recruiting first, the newest first:
Cyprus Institute of Neurology and Genetics · Sites in Italy, United States, Angola and 13 more countries
Ages 2+
Vertex Pharmaceuticals Incorporated · Sites in Italy, United States, Germany and 1 more country
Ages 12–35
Celgene · Sites in Italy, United States, China and 6 more countries
Ages 6–17
Celgene · Sites in Italy, United States, Australia and 19 more countries
Ages 18+
University of Milano Bicocca · Sites in Italy
Ages 2–18 · Healthy volunteers
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 43 beta-Thalassemia studies recruiting now, 10 (23%) set no upper age limit and 31 (72%) stop at 75 or younger; 34 take children under 18; 6 take healthy volunteers.
This study: 3 Years to 35 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
49 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 21 · Phase 3 13 · Phase 4 4
First in 2000; this study’s year is marked. 1 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 9 is below the median of 40 across 209 interventional studies indexed under beta-Thalassemia.
Median enrollment 55 across the 39 interventional studies, 120 across the 10 observational. Of the 29 that completed or were terminated, 15 (52%) have results posted.
This tab as a report to print or save as PDF → With an account.
29 of 49 have an industry lead sponsor. The 10 most frequent:
Fondazione Telethon is the lead sponsor of 12 studies on the registry; 3 are open to participants now.
Fondazione Telethon has 1 study filed under beta-Thalassemia — fewer than ten, so there is no comparison to draw.
5 of the studies in beta-Thalassemia with a site in Italy that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05477563Phase 3Vertex Pharmaceuticals IncorporatedEvaluation of Efficacy and Safety of a Single Dose of CTX001 in Participants With Transfusion-Dependent β-Thalassemia and Severe Sickle Cell Disease | 2027-06-09 |
| NCT05356195Phase 3Vertex Pharmaceuticals IncorporatedEvaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Transfusion-Dependent β-Thalassemia (TDT) | 2027-11-14 |
| NCT06421636Regeneron PharmaceuticalsA Study to Test the Safety, Tolerability, and Efficacy of an Antibody, REGN7999, Injected Under the Skin for the Treatment of Iron Overload in Adult Participants With Non-Transfusion Dependent β-thalassemia, Using MRI Scans to Measure Iron Levels in the Body | 2026-12-03 |
| NCT01639690San Rocco Therapeuticsß-Thalassemia Major With Autologous CD34+ Hematopoietic Progenitor Cells Transduced With TNS9.3.55 a Lentiviral Vector Encoding the Normal Human ß-Globin Gene | 2027-07 |
| NCT05799118Cyprus Institute of Neurology and GeneticsStudy of the Role of Genetic Modifiers in Hemoglobinopathies | 2027-09-30 |
Add all 5 to your calendar (.ics) → With an account.
Among the 49 studies in beta-Thalassemia with a site in Italy, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a prospective, dual-centre, single dose, Phase IIb, single arm, open label study. The proposed clinical trial involves a single infusion of autologous HSPCs genetically modified with the GLOBE lentiviral vector, using an improved transduction protocol in 9 patients affected by transfusion dependent Beta-Thalassemia.
Four study phases are foreseen:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Adequate cardiac, renal, hepatic and pulmonary functions resulting in eligibility to undergo HSCT as evidenced by:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Karnofsky performance status (KPS)
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Genetic: FT007
Autologous hematopoietic stem and progenitor cells (HSPCs) transduced ex vivo with the lentiviral vector GLOBE encoding for the human beta globin using an improved transduction protocol, re-suspended in their final formulation medium and cryopreserved.
Proportion of subjects who achieve TI12 in the 2 years from DP administration
Proportion of Subjects achieving transfusion independence defined as a weighted average Hb ≥ 9.0 gr/dL without any red blood cell transfusion for a continuous period of ≥ 12 months (TI12) at any time during the study after the drug product administration The assessment of TI12 starts 60 days after last RBC transfusion for post-transplant support or BTHAL standard of care.
Time frame: from 60 days after the IMP infusion, to 24 months of follow-up
Overall survival
Overall survival at 12 and 24 months post IMP infusion
Time frame: 12 months and 24 months post IMP infusion
Proportion of Subjects who achieve hematological engraftment ≤ day +60 from DP administration
Proportion of Subjects who achieve hematological engraftment ≤ day +60 from DP administration defined as first day of absolute neutrophil count ≥ 0.5 x 10\^9/L on 3 consecutive measurements obtained on different days and platelets ≥20x 10\^9/L in the absence of platelet transfusions and/or growth factor support for at least 7 consecutive days.
Time frame: from Day 11 to Day 60 post IMP infusion
Frequency and severity of adverse events (AEs) and serious adverse events (SAEs) (Safety and tolerability of the administration of FT007)
Frequency and severity of adverse events (AEs) and serious adverse events (SAEs) attributed to procedures related to harvesting of HSPCs, conditioning regimen, FT007 administration (from screening to 24 months post GT).
Time frame: from Baseline to 24 months post IMP infusion
Proportion of Subjects with abnormal clonal proliferation development due to insertional mutagenesis
Proportion of Subjects with abnormal clonal proliferation development due to insertional mutagenesis
Time frame: 6, 12, 18 and 24 months post IMP infusion
Polyclonal and multilineage engraftment evaluated by VCN and ISA
ISA will be carried out at 3, 6, 12, 18, 24 months on total nucleated cells and different hematopoietic lineages (granulocytes, lymphocytes, erythroid cells) from PB and/or BM. The criteria to assess "polyclonality" of hematopoiesis is defined as \> 1000 unique integration sites retrieved at 3, 6, 12, 18 and 24 months after gene therapy from PB and/or BM cells when available. Clonal dominance will be assessed from 3 months after GT and will be defined as the presence of a vector integration that constitutes \> 30% with respect to the total integrations retrieved from whole peripheral blood cells in at least 3 consecutive timepoints and with an increase in the relative contribution over time. Vector-specific quantitative PCR will be performed on PB and/or BM erythroid cells at screening, 1, 2, 3, 6, 12,18 and 24 months after GT (at 1 and 18 months only on PB, at 24 months after GT. Adequate engraftment is defined as ≥ 0.8 VCN/genome on BM erythroid cells and CD15+ cells.
Time frame: screening, 1, 2, 3, 6, 12, 18 and 24 months after IMP infusion
Proportion of Subjects with immune reconstitution
Proportion of Subjects with immune reconstitution defined as CD4+ \>200 at 6 and 12 months post GT. Immune-monitoring will be evaluated at baseline and at follow-up time points (6 and 12 months of follow-up). The frequency and functionality of lymphoid compartment (B, T, NK cells) in PB and BM, including humoral and cellular responses will be evaluated.
Time frame: 6 and 12 months post IMP infusion
Characterization of Subjects achieving TI12
Duration of TI12 and the time from IMP infusion to last RBC transfusion prior to becoming TI12 will be evaluated. Weighted average Hb during TI12 and the proportion of subjects who meet the definition of TI12 at 24 months will be also evaluated.
Time frame: 24 months after IMP infusion
Characterization of transfusion reduction (TR) among subjects not achieving TI12
Percentage of treated subjects with a reduction in the ml/kg RBC transfused from Month 12 through Month 24 (a 12-month period) after DP infusion of at least 50%, 60%, 75%, 90% or 100% compared to the average annual ml/kg RBC transfusion requirement during the 2 years prior to enrolment will be recorded. Moreover, the number of transfusions from Month 12 through Month 24 compared to the average number of annual transfusions during the 2 years prior to enrolment will be collected and analyzed. Two years of retrospective pre-transplant data will be collected for each subject in the study, so that each subject may serve as his/her own control for the parameters of RBC transfusion requirements.
Time frame: 12 and 24 months post IMP infusion
Health-related quality of life (HRQoL) - PedsQL
HRQoL will be assessed by the use of standardized questionnaires: PedsQL quality of life version 4.0 up to 25 years of age, according to patient's age. PedsQL quality of life will be assessed at 12 and 24 months of follow-up compared to baseline.
Time frame: baseline, 12 and 24 months
Health-related quality of life (HRQoL) - FACT BMT
HRQoL will be assessed by the use of standardized questionnaires: FACT BMT version 4 for adults. FACT BMT will be assessed at 12 and 24 months of follow-up compared to baseline.
Time frame: baseline, 12 and 24 months
Health-related quality of life (HRQoL) - EQ-5D-5L
HRQoL will be assessed by the use of standardized questionnaires: EuroQol Quality of Life Scale-5 dimensions-5 levels of severity (EQ-5D-5L) for adults
Time frame: baseline, 12 and 24 months
Health-related quality of life (HRQoL) - EQ-5D-Y
HRQoL will be assessed by the use of standardized questionnaires: EuroQol Quality of Life Scale-5 dimensions-5 levels of severity the EuroQol Quality of Life Scale-5 dimensions youth (EQ-5D-Y) for children and adolescents.
Time frame: baseline, 12 and 24 months
Proportion of Subjects with engraftment of genetically corrected cells
Proportion of Subjects with engraftment of genetically corrected cells (expressed as VCN ≥ 0.8 on bone marrow erythroid cells and CD15+ cells). Engraftment will be assessed by vector-specific quantitative PCR on bone marrow erythroid cells at 6, 12, and 24 months after IMP infusion.
Time frame: 6, 12, and 24 months after IMP infusion
Levels of biomarkers indicative of ineffective erythropoiesis before and after gene therapy at different time points.
Evaluation of plasma iron level, erythropoietin (EPO), soluble serum transferrin receptor (sTfR), Lactate Dehydrogenase (LDH) and Bilirubin will be evaluated as surrogate of ineffective erythropoiesis at screening and 1, 3, 6, 12, 24 months. Decreased levels of these parameters correlate with ineffective erythropoiesis improvement.
Time frame: screening and 1, 3, 6, 12, 24 months after IMP infusion
Shear Wave Elastography and Liver Iron Concentration (LIC) over time
Shear Wave Elastography and LIC will be performed at screening and at 12, 24 months after infusion of DP (T2\*MRI at screening can be avoided if performed less than 6 months before enrolment at treatment sites); in selected cases liver biopsy can be performed.
Time frame: screening, 12 and 24 months after IMP infusion
Cardiac T2* value over time
Cardiac T2\* value will be assessed through T2\*MRI at screening and at 12, 24 months after infusion of DP (T2\*MRI at screening can be avoided if performed less than 6 months before enrolment at treatment sites).
Time frame: screening, 12 and 24 months after IMP infusion
Ferritin serum levels over time
Serum ferritin will be evaluated at screening, 3, 6, 12, 18, 24 months after infusion of DP.
Time frame: screening, 3, 6, 12, 18 and 24 months after IMP infusion
Proportion of patients free from any iron-chelating therapy, including regular phlebotomies at month 24
The proportion of patients free from iron-chelation therapy, including regular phlebotomies in the entire cohort will be evaluated at month 24 after infusion of DP.
Time frame: 24 months after IMP infusion
Duration of iron-chelating treatment after DP infusion
The duration of iron chelation therapy following DP infusion will be assessed. This includes the time from DP infusion to the last documented administration of iron chelation treatment.
Time frame: from Day 1 to 24 months post IMP infusion
Plan to share: No
No publications or documents are linked to this record.
Started Jul 2026 (actual). Primary completion is estimated for Oct 2028, 27 months after the start.
Of 29 phase 2 interventional studies under beta-Thalassemia, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 57. This study's planned 27 months is below that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Fondazione Telethon